Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer

被引：1
|
作者：
Koshkin, V. S. [1 ]
Sun, Y. [2 ]
Osterman, C. K. [3 ]
Natesan, D. [4 ]
Su, C. [5 ]
Lemke, E. [6 ]
Khaki, A. R. [7 ]
Johnson, A. [8 ]
Owens, X. [9 ]
Park, J. J. [5 ]
Basu, A. [9 ]
Barata, P. M. Coelho [8 ]
Davis, N. [10 ]
Grivas, P. [11 ]
Milowsky, M. [3 ]
Kilari, D. [6 ]
Alva, A. [5 ]
机构：
[1] UCSF, Helen Diller Family Comprehens Canc Ctr, Dept Med, Div Med Oncol, San Francisco, CA USA
[2] Univ Michigan, Biostat, Ann Arbor, MI USA
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] UCSF, Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol, San Francisco, CA USA
[5] Univ Michigan, Med, Ann Arbor, MI 48109 USA
[6] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA
[7] Univ Washington, Med, Seattle, WA 98195 USA
[8] Tulane Univ, Dept Med Oncol, New Orleans, LA 70118 USA
[9] Univ Alabama Birmingham, Med, Birmingham, AL USA
[10] Vanderbilt Univ, Med Ctr, Med, Nashville, TN USA
[11] Univ Washington, Seattle Canc Care Alliance, Hematol Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.843
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
771P
引用
收藏
页码：S594 / S594
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
    Wu, Qiuji
    Qin, Yi
    Liao, Weiting
    Zhang, Mengxi
    Yang, Yang
    Zhang, Pengfei
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [42] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Kirollos S. Hanna
    Drugs, 2020, 80 : 1 - 7
  • [43] Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    ANTICANCER RESEARCH, 2024, 44 (07) : 3025 - 3032
  • [44] FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
    Chang, Elaine
    Weinstock, Chana
    Zhang, Lijun
    Charlab, Rosane
    Dorff, Sarah E.
    Gong, Yutao
    Hsu, Vicky
    Li, Fang
    Ricks, Tiffany K.
    Song, Pengfei
    Tang, Shenghui
    Waldron, Peter E.
    Yu, Jingyu
    Zahalka, Eias
    Goldberg, Kirsten B.
    Pazdur, Richard
    Theoret, Marc R.
    Ibrahim, Amna
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 922 - 927
  • [45] Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
    Teo, Min Yuen
    Ratna, Neha
    Regazzi, Ashley Marie
    Zimmerman, Danielle Elise
    McHugh, Deaglan Joseph
    Laccetti, Andrew Leonard
    Xiao Han
    Lee, Chung-Han
    Aggen, David Henry
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] Enfortumab Vedotin Nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma
    Pace, Amanda
    Brower, Blaine
    Conway, Dawn
    Leis, Dayna
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2021, 25 (02) : E1 - E9
  • [47] Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
    Jindy, Tanya
    Jiang, Cindy Y.
    Alhalabi, Omar
    Nguyen, Charles B.
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Brown, Jason R.
    Kilari, Deepak
    Emamekhoo, Hamid
    Hoimes, Christopher J.
    Khaki, Ali Raza
    Gupta, Shilpa
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 652 - 652
  • [48] Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era
    Kita, Yuki
    Ito, Katsuhiro
    Sano, Tomoyasu
    Hashimoto, Kohei
    Mochizuki, Takanori
    Shiraishi, Yusuke
    Araki, Hiromasa
    Fujiwara, Maki
    Kanamaru, Sojun
    Takahashi, Takehiro
    Hishiki, Kosuke
    Okada, Takuya
    Ogawa, Kosuke
    Ito, Masaaki
    Kojima, Takahiro
    Nishiyama, Naotaka
    Matsui, Yoshiyuki
    Nishiyama, Hiroyuki
    Kitamura, Hiroshi
    Kobayashi, Takashi
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (07) : 647 - 655
  • [49] Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
    Minato, Akinori
    Takaba, Tomohisa
    Sugita, Yoshihiro
    Kaneko, Yuya
    Hongyo, Ryota
    Tanaka, Toshinobu
    Bando, Taro
    Sugi, Takaomi
    Mizushima, Yui
    Matsukawa, Takuo
    Jojima, Kazumasa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Kashiwagi, Eiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [50] Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients With Locally Advanced Metastatic Urothelial Carcinoma
    Van Sanden, Suzy
    Youssef, Ayman
    Baculea, Simona
    Stubbs, Keith
    Triantos, Spyros
    Yuan, Zijiao
    Daly, Caitlin
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2024, 11 (02): : 49 - 57
12345